Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we?

by Zuzaan Zulzaga, Erdenetuya Myagmarsuren, Herman J. Woerdenbag, Eugene P. van Puijenbroek
Published 2021-03-01

Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review

by Tanja Fens, Pieter T. de Boer, Eugène P. van Puijenbroek, Maarten J. Postma
Published 2021-02-01

Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and Policy

by Tanja Fens, Tanja Fens, Tanja Fens, Eugène P. van Puijenbroek, Eugène P. van Puijenbroek, Maarten J. Postma, Maarten J. Postma, Maarten J. Postma, Maarten J. Postma, Maarten J. Postma, Maarten J. Postma
Published 2021-04-01

Tamsulosin Associated with Interstitial Lung Damage in CYP2D6 Variant Alleles Carriers

by Naomi T. Jessurun, Petal A. Wijnen, Aalt Bast, Eugène P. van Puijenbroek, Otto Bekers, Marjolein Drent
Published 2020-04-01

Safe use of radiopharmaceuticals in patients with chronic kidney disease: a systematic review

by Nanno Schreuder, Iris de Romijn, Pieter L. Jager, Jos G. W. Kosterink, Eugène P. van Puijenbroek
Published 2021-08-01

The International Pharmacy Game: A Comparison of Implementation in Seven Universities World-Wide

by Tanja Fens, Denise L. Hope, Sarah Crawshaw, Eline Tommelein, Claudia Dantuma-Wering, Bertha Maria Verdel, Indrė Trečiokienė, Vibhu Solanki, Eugène P. van Puijenbroek, Katja Taxis
Published 2021-07-01

Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands

by Pieter J. Glerum, Marc Maliepaard, Vincent deValk, Joep H.G. Scholl, Florence P.A.M. vanHunsel, Eugène P. vanPuijenbroek, David M. Burger, Kees Neef
Published 2020-05-01